Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Tsiodras, Sotirios ^a   Georgoulakis, John ^a   Chranioti, Aikaterini ^a,b   Voulgaris, Zanis ^b   Psyrri, Amanda ^b   Tsivilika, Angeliki ^c   Panayiotides, John ^a   Karakitsos, Petros ^a,b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASSAY; CANCER GRADING; COLPOSCOPY; CONDYLOMA ACUMINATUM; CORRELATION ANALYSIS; CYTOLOGY; FEMALE; GREECE; HISTOLOGY; HUMAN; HYBRID CAPTURE; INFECTION RISK; INTERMETHOD COMPARISON; KAPPA STATISTICS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTION; REPRODUCIBILITY; SAMPLE SIZE; UNIVERSITY HOSPITAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS; BIOPSY; CANCER INVASION; GENETICS; METHODOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; BIOPSY; COLPOSCOPY; CYTOLOGICAL TECHNIQUES; FEMALE; GREECE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 77649293756     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-53     Document Type: Article

References (41)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(11):796-802. 10.1093/jnci/87.11.796, 7791229.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24S3:S1-S10.
4. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88(1):63-73. 10.1038/sj.bjc.6600688, 2376782, 12556961.
5. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006, 98(5):303-315.
6. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527. 10.1056/NEJMoa021641, 12571259.
7. Ames A, Gravitt P. Human papillomavirus vaccine update. Curr Infect Dis Rep 2007, 9(2):151-158. 10.1007/s11908-007-0011-6, 17324353.
8. Sahebali S, Depuydt CE, Boulet GA, Arbyn M, Moeneclaey LM, Vereecken AJ, Van Marck EA, Bogers JJ. Immunocytochemistry in liquid-based cervical cytology: analysis of clinical use following a cross-sectional study. Int J Cancer 2006, 118(5):1254-1260. 10.1002/ijc.21489, 16161049.
9. Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006, 106(5):1054-1064. 10.1002/cncr.21664, 16421920.
10. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. Jama 2002, 287(16):2114-2119. 10.1001/jama.287.16.2114, 11966386.
11. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. Blaustein's pathology of the female genital tract 2002, 253-324. New York: Springer, Kurman RJ, 5.
12. de Roda Husman AM, Walboomers JM, Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995, 76(Pt 4):1057-1062. 10.1099/0022-1317-76-4-1057, 9049358.
13. Pao CC, Lin CY, Maa JS, Lai CH, Wu SY, Soong YK. Detection of human papillomaviruses in cervicovaginal cells using polymerase chain reaction. J Infect Dis 1990, 161(1):113-115.
14. Giard RW, Hermans J. The evaluation and interpretation of cervical cytology: application of the likelihood ratio concept. Cytopathology 1993, 4(3):131-137. 10.1111/j.1365-2303.1993.tb00078.x, 8343590.
15. Clavel C, Masure M, Levert M, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol 2000, 9(3):145-150. 10.1097/00019606-200009000-00004, 10976721.
16. Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, Schussler JE, Schiffman M. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol 2002, 40(3):1088-1090. 10.1128/JCM.40.3.1088-1090.2002, 120262, 11880448.
17. Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998, 36(11):3248-3254. 105310, 9774574.
18. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004, 42(6):2470-2475. 10.1128/JCM.42.6.2470-2475.2004, 427873, 15184422.
19. Yamazaki H, Sasagawa T, Basha W, Segawa T, Inoue M. Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer 2001, 94(2):222-227. 10.1002/ijc.1455, 11668502.
20. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, Fukuchi T, Kubushiro K, Tsukazaki K, Nozawa S. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. Br J Cancer 2003, 88(12):1883-1888. 10.1038/sj.bjc.6601023, 2741123, 12799631.
21. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999, 81(3):554-558. 10.1038/sj.bjc.6690730, 2362918, 10507785.
22. Meijer CJ, Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992, (119):271-281.
23. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995, 172(3):946-954. 10.1016/0002-9378(95)90026-8, 7892889.
24. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354(9172):20-25. 10.1016/S0140-6736(98)12490-X, 10406360.
25. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999, 281(17):1605-1610. 10.1001/jama.281.17.1605, 10235153.
26. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R, Quereux C, Birembaut P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80(9):1306-1311. 10.1038/sj.bjc.6690523, 2363085, 10424730.
27. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999, 8(3):157-164. 10.1097/00019606-199909000-00009, 10565688.
28. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006, 24(Suppl 3):S90-97.
29. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92(10):818-825. 10.1093/jnci/92.10.818, 10814677.
30. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169(2):235-240.
31. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95(1):46-52.
32. Kjaer SK, Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002, 325(7364):572. 10.1136/bmj.325.7364.572, 124551, 12228133.
33. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001, 84(12):1616-1623. 10.1054/bjoc.2001.1845, 2363679, 11401314.
34. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005, 191(5):731-738. 10.1086/427557, 15688287.
35. Richart RM, Masood S, Syrjanen KJ, Vassilakos P, Kaufman RH, Meisels A, Olszewski WT, Sakamoto A, Stoler MH, Vooijs GP, et al. Human papillomavirus. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 1998, 42(1):50-58.
36. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 2003, 127(8):959-968.
37. Kaufman RH, Adam E, Icenogle J, Reeves WC. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness. Am J Obstet Gynecol 1997, 177(4):930-936. 10.1016/S0002-9378(97)70296-5, 9369847.
38. Nuovo GJ. Detection of human papillomavirus in Papanicolaou smears: correlation with pathologic findings and clinical outcome. Diagn Mol Pathol 1998, 7(3):158-163. 10.1097/00019606-199806000-00006, 9836071.
39. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87(18):1365-1371. 10.1093/jnci/87.18.1365, 7658497.
40. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995, 61(3):306-311. 10.1002/ijc.2910610305, 7729939.
41. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350. 10.1038/nrc798, 12044010.